Phase 1 Obesity Trial, Recruiting (NCT07566390)

Phase 1 Obesity Trial, Recruiting NCT07566390 Sponsor: Novo Nordisk A/S Condition: Obesity

Printed from Voxsanity (voxsanity.com.au) — NCT07566390 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Obesity

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are male or female, aged between 18 and 55 years old at the time of signing the consent form
People with a Body Mass Index (BMI) between 25.0 and 34.9, where the higher weight is due to excess body fat, as determined by the study doctor
People who the study doctor considers to be in suitable health based on their medical history, physical check-up, heart tracing, blood pressure readings, and blood or urine test results taken during screening appointments

Who may not be able to join:

People with a known or suspected allergy or sensitivity to the study treatment or similar products
People who have any health condition that the study doctor believes could put them at risk or make it difficult to safely follow the study's requirements
People whose blood sugar control reading (called HbA1c) is 6.5% or higher at the screening appointment, which can be a sign of diabetes

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Phone: (+1) 866-867-7178

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07566390

Sponsor: Novo Nordisk A/S

Phase: Phase 1

Status: Recruiting

Condition: Obesity

Trial contact: (+1) 866-867-7178

More information: https://clinicaltrials.gov/study/NCT07566390

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are male or female, aged between 18 and 55 years old at the time of signing the consent form
People with a Body Mass Index (BMI) between 25.0 and 34.9, where the higher weight is due to excess body fat, as determined by the study doctor
People who the study doctor considers to be in suitable health based on their medical history, physical check-up, heart tracing, blood pressure readings, and blood or urine test results taken during screening appointments

Who may not be able to join:

People with a known or suspected allergy or sensitivity to the study treatment or similar products
People who have any health condition that the study doctor believes could put them at risk or make it difficult to safely follow the study's requirements
People whose blood sugar control reading (called HbA1c) is 6.5% or higher at the screening appointment, which can be a sign of diabetes

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Novo Nordisk A/S

Registry

ClinicalTrials.gov

Start date

1 May 2026

Est. completion

26 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of treatment emergent adverse events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov